• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 23
  • 17
  • 10
  • 4
  • 3
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 66
  • 66
  • 44
  • 40
  • 39
  • 32
  • 22
  • 21
  • 20
  • 19
  • 18
  • 11
  • 11
  • 10
  • 10
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
51

Behavioral effects of deep brain stimulation in the subthalamic nucleus in obsessive compulsive disorder

Antonsson, Rebecka January 2021 (has links)
Obsessive compulsive disorder (OCD) is one of the most disabling psychiatric disorder. About 10% of patients with OCD do not respond to pharmacological treatment. However, deep brain stimulation (DBS) has advanced as an alternative treatment. In 2002, two patients who suffered from co-morbidity of Parkinson’s disease (PD) and OCD were treated with DBS for their PD, with DBS-electrodes placed in the subthalamic nucleus (STN). Surprisingly, not only PD symptoms but also OCD symptoms were improved. This was the first time that patients with OCD were treated with DBS in STN and it was found to markedly improve their symptoms. When performing DBS in patients with OCD, as well as for treating PD, several side-effectshave been observed. The side-effects can be both physical and psychological. In this project,the aim is to investigate the efficiency and side-effects of DBS in OCD, correlated with the position of the electrode in, or near, the STN. To address the aim, 10 published reports were analysed. It was found that all electrode positions reported resulted in great improvement of OCD symptoms. In fact, 88% of patients had significant improvement. There was no clear correlation between position of the electrode and number or type of side-effect. However, there was a trend that patients with the electrode placed in associative/limbic STN suffered from more side-effects. In conclusion, this project demonstrates that there might be a correlation between target for electrode stimulation and side-effects. It would be interesting analyse this closer, including additional electrode target areas, but also consider other possible explanations for the variety of side-effects caused by DBS for OCD.
52

Across Borders : A Histological and Physiological Study of the Subthalamic Nucleus in Reward and Movement

Schweizer, Nadine January 2016 (has links)
The basal ganglia are the key circuitry controlling movement and reward behavior. Both locomotion and reward-related behavior are also modified by dopaminergic input from the substantia nigra and the ventral tegmental area (VTA). If the basal ganglia are severed by lesion or in disease, such as in Parkinson’s disease, the affected individuals suffer from severe motor impairments and often of affective and reward-related symptoms. The subthalamic nucleus (STN) is a glutamatergic key area of the basal ganglia and a common target for deep brain stimulation in Parkinson’s disease to alleviate motor symptoms. The STN serves not only motoric, but also limbic and cognitive functions, which is often attributed to a tripartite anatomical subdivision. However, the functional output of both VTA and STN may rely more on intermingled subpopulations than on a strictly anatomical subdivision. In this doctoral thesis, the role of subpopulations within and associated with the basal ganglia is addressed from both a genetic and a behavioral angle. The identification of a genetically defined subpopulation within the STN, co-expressing Paired-like homeodomain transcription factor 2 (Pitx2) and Vesicular glutamate transport 2 (Vglut2), made it possible to conditionally reduce glutamatergic transmission from this subgroup of neurons and to investigate its influence on locomotion and motivational behavior, giving interesting insights into the mechanisms possibly underlying deep brain stimulation therapy and its side-effects. We address the strong influence of the Pitx2-Vglut2 subpopulation on movement, as well as the more subtle changes in reward-related behavior and the impact of the alterations on the reward-related dopaminergic circuitry. We also further elucidate the genetic composition of the STN by finding new markers for putative STN subpopulations, thereby opening up new possibilities to target those cells genetically and optogenetically. This will help in future to examine both STN development, function in the adult central nervous system and defects caused by specific deletion. Eventually identifying and characterizing subpopulations of the STN can contribute to the optimization of deep brain stimulation and help to reduce its side-effects, or even open up possibilities for genetic or optogenetic therapy approaches.
53

Etude anatomique et fonctionnelle des controles exerces par les recepteurs serotoninergiques2C au sein des ganglions de la base / Anatomical and Functional Study of the Serotonin2C Receptors Controls in the Basal Ganglia

Lagiere, Mélanie 30 October 2013 (has links)
Ce travail de neurobiologie intégrative porte sur l’étude des contrôles exercés par les récepteurs 5-HT2C au niveau du réseau des ganglions de la base, un groupe de structures sous-corticales impliquées dans le contrôle du comportement moteur. Les récepteurs 5-HT2C exercent trois modalités de contrôle sur les cellules des ganglions de la base comprenant les contrôles phasique, tonique et constitutif, ce dernier contrôle étant indépendant de la présence de la sérotonine (5-HT), le ligand endogène. A l’aide d’outils pharmacologiques appropriés (agoniste, antagoniste et agoniste inverse), nous avons étudié chez le rat les différents contrôles des récepteurs 5-HT2C sur un comportement moteur, les mouvements orofaciaux. Nous avons aussi étudié ces contrôles dans les ganglions de la base en mesurant l’expression du marqueur neuronal de changement d’activité cellulaire, le proto-oncogène c-Fos, et en utilisant des enregistrements extracellulaires unitaires de la fréquence basale ou évoquée par des stimulations corticales des structures de sortie du réseau, le noyau entopédonculaire (NEP) ou la substance noire pars reticulata (SNr). Mes données montrent que la stimulation du récepteur 5-HT2C ou le blocage de son activité constitutive entrainent une augmentation des mouvements orofaciaux anormaux. Les données anatomiques révèlent que les différents contrôles 5-HT2C s’expriment au niveau des structures d’entrées des ganglions de la base, le striatum et le noyau sous-thalamique (NST), avec une expression préférentielle de l’activité constitutive au niveau du striatum et du noyau accumbens (NAc). Le contrôle phasique et l’activité constitutive étendent leur influence vers les structures de sortie des ganglions de la base ce qui pourrait être associé à l’émergence des mouvements orofaciaux anormaux. Les contrôles 5-HT2C sont influencés par le niveau d’activité du réseau et notamment le niveau de transmission dopaminergique (DA). En effet, une lésion des neurones DA potentialise les réponses comportementales et électrophysiologiques induites par un agoniste 5-HT2C au niveau du NEP. La stimulation des récepteurs D2 entraîne des dyskinésies orofaciales et une augmentation des réponses électrophysiologiques de la voie cortico-sous-thalamo-nigrale et ces effets sont supprimés par des antagonistes 5-HT2C. Ce travail apporte des éléments concernant la distribution et la nature de divers contrôles exercés par les récepteurs 5-HT2C au sein des ganglions de la base. Il ouvre des perspectives thérapeutiques sur l’utilisation des antagonistes 5-HT2C dans la schizophrénie ou la maladie de Parkinson. Pour autant, ces contrôles sont complexes et une meilleure connaissance de leur rôle dans ces régions permettrait de mieux appréhender des thérapies éventuelles avec des agents 5-HT et/ou 5-HT2C. / This work of integrative neurobiology focuses on the study of the controls exerted by the 5-HT2C receptors in the basal ganglia, a group of subcortical structures involved in the control of motor behavior. 5-HT2C receptors exert three modalities of control over cells of the basal ganglia, including a phasic, tonic and a constitutive control, the latter one being independent of the presence of serotonin (5-HT), the endogenous ligand. Using appropriate pharmacological tools (agonist, antagonist and inverse agonist), we have studied in rats the different controls of 5-HT2C receptors on one motor behavior, the purposeless orofacial movements. We also have studied these controls in the basal ganglia by measuring the expression of the proto-oncogene c-Fos, a marker of change of neuronal activity by determining the firing rate, basal or evoked by cortical stimulations, of neurons located in the output structures, the entopeduncular nucleus (EPN) or the substantia nigra pars reticulata (SNr), using single unit extracellular recordings. My data showed that stimulation or the blockade of the constitutive activity of 5-HT2C receptor induced an increase in abnormal orofacial movements. Anatomical data indicated that the different 5-HT2C controls are expressed in the input structures of the basal ganglia, the striatum and the subthalamic nucleus (STN), with a preferential influence of the constitutive activity in the striatum and nucleus accumbens (NAc). In addition, the phasic control and the constitutive activity extended their control to the output structures of the basal ganglia which could be associated with the emergence of orofacial movements. 5-HT2C controls are influenced by the network activity, in particular the level of dopaminergic (DA) transmission. Indeed, a lesion of DA neurons potentiated behavioral and electrophysiological responses induced by a 5-HT2C agonist by acting in the EPN. The stimulation of D2 receptors induced oral dyskinesia and an increase in electrophysiological responses of the cortico-subthalamo-nigral pathway, and these effects were suppressed by selective 5-HT2C antagonists. This work brings up elements regarding the distribution and the nature of the diverse controls exerted by 5-HT2C receptors in the basal ganglia. It opens therapeutic perspectives for the use of 5-HT2C antagonists in the treatment of schizophrenia and Parkinson's disease. Nevertheless, these controls are complex and a better understanding of these controls in these regions would permit to apprehend possible treatments using 5-HT and/or 5-HT2C agents.
54

Implication des systèmes monoaminergiques dans la physiopathologie de la maladie de Parkinson : étude comportementale et électrophysiologique in vivo / Involvement of monoaminergic systems in the pathophysiology of Parkinson’s disease : behavioural and electrophysiological studies in the rat

Delaville, Claire 30 September 2011 (has links)
Depuis les années 60, la maladie de Parkinson est considérée comme une conséquence de la perte des neurones dopaminergiques de la substance noire pars compacta. Cependant, dans les modèles animaux de cette pathologie, la perte dopaminergique seule ne reproduit pas de façon simultanée les symptômes moteurs et non moteurs observés chez les patients. De plus en plus d’études suggèrent l’implication des systèmes noradrénergique et sérotoninergique à la fois dans la manifestation des symptômes mais aussi dans les effets secondaires de la L-Dopa et de la stimulation à haute fréquence (SHF) du noyau sous thalamique (NST). Le travail de cette thèse s’inscrit dans ce champ de recherche visant une meilleure compréhension de la physiopathologie et la thérapie de la maladie de Parkinson.Dans un premier temps, nous nous sommes intéressés au rôle respectif des trois monoamines dans la manifestation des symptômes moteurs et non moteurs ainsi que dans l’activité pathologique de trois structures majeures des ganglions de la base, le NST, la pars reticulata de la substance noire et le globus pallidus. L’ensemble de nos résultats démontre que la perturbation des trois systèmes monoaminergiques joue un rôle important à la fois dans la manifestation des troubles moteurs et non moteurs mais aussi dans l’induction de l’activité électrique pathologique des neurones au sein des ganglions de la base. Dans un second temps, nous avons étudié l’efficacité des traitements antiparkinsoniens sur les troubles moteurs et non-moteurs induits par les différentes déplétions monoaminergiques. Nos résultats montrent que quand la déplétion dopaminergique est associée à la déplétion d’une autre monoamine la SHF du NST présente une efficacité moins importante que celle lors d’une déplétion en dopamine seule. Ceci permet d’expliquer le manque d’efficacité de ce traitement chez certains patients.Enfin, comme peu d’études se sont intéressées au rôle de la noradrénaline dans la modulation de l’activité neuronale au sein des ganglions de la base, nous avons étudié les effets d’agents noradrénergiques injectés localement dans le NST sur le comportement moteur et sur l’activité électrique des neurones du NST. Nos résultats montrent que la modulation noradrénergique au niveau du NST ne dépendait pas de l’innervation dopaminergique au sein des ganglions de la base. De plus, nous avons pu mettre en évidence que les récepteurs alpha1 modulent la fréquence de décharge, tandis que les récepteurs alpha2 jouent un rôle important dans la genèse de l’activité en bouffée des neurones du NST ce qui pourrait être á l’origine des déficits moteurs.Les résultats des travaux de cette thèse ont donc permis d’apporter de nouvelles évidences sur l’implication des trois systèmes monoaminergiques dans la physiopathologie des symptômes moteurs et non moteurs, dans l’activité pathologique des ganglions de la base ainsi que dans l’efficacité des traitements antiparkinsoniens. De plus, nous avons pu montrer que les récepteurs noradrénergiques alpha sont impliqués dans le contrôle de l’activité des neurones du NST et par conséquent dans le contrôle moteur. / The loss of dopamine (DA) nigro-striatal neurons has been the pathophysiological focus of the devastating conditions of Parkinson’s disease, but depletion of DA alone in animal models has failed to simultaneously elicit both the motor and non-motor deficits of PD. There is growing evidence that additional loss of locus coeruleus noradrenaline (NA) and dorsal raphe serotonin (5-HT) neurons in PD could be involved in the clinical expression of many of the observed deficits but also on the efficiency and on the side effects of antiparkinsonian treatments, L-Dopa and High Frequency Stimulation (HFS) of the subthalamic nucleus (STN).First, we focused on the respective role of DA, NA and 5-HT systems on motor and non-motor deficits and on the pathological activity of three basal ganglia nuclei, STN, substantia nigra pars reticulata and globus pallidus. Results of the present study bring new insights into the combined roles of the three monoaminergic systems in the motor and non motor symptoms of PD and also into the pathological activity of basal ganglia nuclei.Second, we studied the involvement of DA, NA and 5-HT depletions on the efficiency of L-Dopa and HFS of STN. Our results show that when DA depletion is combined with another monoamine depletion, STN HFS is less efficient compared to the situation when DA is depleted alone. These data provide a clear explanation on the lack of efficacy of this treatment in some operated parkinsonian patients.Finally, as few studies focused on NAergic modulation of basal ganglia, we studied the effects of NAergic agents locally injected into the STN on motor behavior and also on STN neuronal activity. We show that alpha 1 NAergic receptors are implicated in the modulation of firing rate and that alpha 2 receptors play an important role in the emergence of burst activity, which could be at the origin of motor deficits.Results of this thesis provide new evidences on the involvement of the three monoaminergic systems in motor and non motor symptoms and also in the efficiency of antiparkinsonian treatments. Moreover, we show that NAergic alpha receptors are implicated in the control of STN neuronal activity and consequently in the motor control.
55

Contrôle cognitif dans la maladie de Parkinson : étude par les tests de fluences verbales et la Simon Task motivée / Cognitive action control in Parkinson's disease : study with the verbal fluency tests and the rewarded Simon Task

Houvenaghel, Jean-François 14 March 2016 (has links)
La symptomatologie non motrice de la maladie de Parkinson s’accompagne fréquemment d’un défaut de contrôle cognitif. Le contrôle cognitif faisant référence à un ensemble de processus facilitant le traitement de l’information et la production de comportements adaptés, son altération impactera de très nombreuses capacités cognitives. Parmi ces capacités, nous nous intéresserons plus spécifiquement, d’une part, à la production orale de mots évaluée à travers les tests de fluences verbales et, d’autre part, aux processus favorisant la production d’actions intentionnelles en situation motivée comme évaluée par la Simon Task motivée. Par notre première étude nous remettrons en question l’hypothèse d’un défaut de contrôle cognitif comme origine principale de la réduction des performances aux tests de fluences verbales à la suite de la stimulation cérébrale profonde du noyau subthalamique. En effet, nous n’avons pas mis en évidence de relation entre cette altération et une modification de l’activité métabolique des régions frontales supportant le contrôle cognitif, ou une modification des performances à d’autres tests nécessitant un contrôle cognitif efficient. Les travaux suivant, portant sur le contrôle des actions motivées démontrent, d’une part, que la production d’actions guidées, non pas par des tendances d’actions impulsives, mais par des tendances d’actions en accord avec les intentions, est plus ardue lorsqu’une récompense financière est mise en jeu. D’autre part, le traitement de la maladie de Parkinson, aussi bien par dopathérapie que par stimulation cérébrale profonde du noyau sous-thalamique module le fonctionnement des processus impliqués, suggérant un rôle particulier des noyaux gris centraux. Nous discuterons des processus cognitifs et neuronaux impliqués et proposerons des perspectives de recherche aussi bien neuroscientifiques que cliniques. / The nonmotor symptoms of Parkinson’s disease frequently include a cognitive control deficit. Cognitive control refers to a set of processes that promote information processing and the production of appropriate behaviours, so its impairment can have an impact on a wide range of cognitive abilities. We focused on just two of these abilities: oral word production, as assessed with phonemic and semantic verbal fluency tests; and cognitive action control in an incentive context, as assessed with a rewarded Simon Task. In our first study, we questioned the hypothesis that the reduction in verbal fluency performances observed following surgery for subthalamic nucleus deep-brain stimulation is mainly due to a cognitive control deficit. Results failed to reveal a relationship between this reduction and either modified metabolic activity in the frontal regions subtending cognitive control or modified performances on other tests requiring efficient cognitive control. In our second and third studies, investigating cognitive action control in an incentive context, we showed that the production of intention-driven actions, as opposed to impulsive ones, is more difficult when a monetary reward is at stake. We also demonstrated that treatment for Parkinson’s disease, whether it takes the form of dopaminergic medication or subthalamic stimulation, modulates the functioning of these processes, suggesting that the basal ganglia have a role in them. We discuss the cognitive and neural processes involved and outline future avenues for both neuroscientific and clinical research.
56

Rôle du noyau subthalamique et de ses afférences hyperdirectes provenant du cortex préfrontal dans le codage et la recherche de récompense chez le rat / Role of the subthalamic nucleus and its prefrontal afferences of the hyperdirect pathway in reward processes and coding in rats

Tiran-Cappello, Alix 02 October 2018 (has links)
La stimulation cérébrale profonde (SCP) est actuellement un traitement efficace pour la maladie de parkinson. Cette approche est maintenant fortement envisagée pour le traitement des addictions. Elle consiste à délivrer des impulsions électriques au sein d’une structure cérébrale : le noyau subthalamique. Nous avons montré dans le noyau subthalamique l’existence de signatures associée à la transition vers l’addiction et la prise compulsive de drogue, ainsi que le potentiel thérapeutique de la SCP pour réduire la consommation pathologique et compulsive de cocaïne chez des rats. Nous avons également montré le contrôle spécifique du noyau subthalamique sur la motivation pour la nourriture sucrée et les drogues d’abus. Dans l’ensemble, cette thèse devrait permettre une meilleure compréhension des mécanismes de la SCP, de son potentiel thérapeutique pour les addictions et de ses éventuels effets secondaires. / Deep brain stimulation (DBS) is currently one form of effective treatment for Parkinson’s disease. This approach is currently considered for the treatment of addiction. It consists in the delivery of small electric impulses inside a brain structure: the subthalamic nucleus. We have shown in the subthalamic nucleus the existence of signature associated with the transition to addiction and compulsive drug abuse, as well as the therapeutic potential of DBS to reduce pathological intake and compulsive cocaine abuse in rats. We also established the specific control exerted by the subthalamic nucleus on the motivation for sweet food and drug of abuse. Overall this thesis could allow a better understanding of the mechanisms of DBS, its therapeutic potential in addiction and possible side effects.
57

Preclinical Modeling of Treatment-induced Impulsivity in Parkinson's Disease

Aleksandrova, Lily R 20 November 2013 (has links)
Dopamine agonist therapy and deep brain stimulation (DBS) are both linked to increased impulsivity in Parkinson’s disease (PD), but the underlying mechanisms remain unclear. We trained intact and PD-like rats on a rat gambling task (rGT) measuring impulsive choice and premature responding. Animals were then retested with/without treatment, pramipexole (PPX) or DBS, administered chronically prior to rGT testing. Early PD-like rats did not exhibit major differences in rGT performance or treatment response. Our work suggests that DBS and PPX are not intrinsically linked with increases in impulsivity. Neither DBS nor PPX disrupted gambling-like behaviour in our paradigm, while differential effects on premature and perseverant responding in the task were observed with treatment. Based on our findings, the previously reported ability of PPX to increase impulsive choice might not be mediated by the dopamine D3 receptor. Interestingly, our work suggests that the effects of STN-DBS on impulse control might be amplitude-dependent.
58

Preclinical Modeling of Treatment-induced Impulsivity in Parkinson's Disease

Aleksandrova, Lily R 20 November 2013 (has links)
Dopamine agonist therapy and deep brain stimulation (DBS) are both linked to increased impulsivity in Parkinson’s disease (PD), but the underlying mechanisms remain unclear. We trained intact and PD-like rats on a rat gambling task (rGT) measuring impulsive choice and premature responding. Animals were then retested with/without treatment, pramipexole (PPX) or DBS, administered chronically prior to rGT testing. Early PD-like rats did not exhibit major differences in rGT performance or treatment response. Our work suggests that DBS and PPX are not intrinsically linked with increases in impulsivity. Neither DBS nor PPX disrupted gambling-like behaviour in our paradigm, while differential effects on premature and perseverant responding in the task were observed with treatment. Based on our findings, the previously reported ability of PPX to increase impulsive choice might not be mediated by the dopamine D3 receptor. Interestingly, our work suggests that the effects of STN-DBS on impulse control might be amplitude-dependent.
59

Motion and Emotion : Functional In Vivo Analyses of the Mouse Basal Ganglia

Arvidsson, Emma January 2014 (has links)
A major challenge in the field of neuroscience is to link behavior with specific neuronal circuitries and cellular events. One way of facing this challenge is to identify unique cellular markers and thus have the ability to, through various mouse genetics tools, mimic, manipulate and control various aspects of neuronal activity to decipher their correlation to behavior. The Vesicular Glutamate Transporter 2 (VGLUT2) packages glutamate into presynaptic vesicles for axonal terminal release. In this thesis, VGLUT2 was used to specifically target cell populations within the basal ganglia of mice with the purpose of investigating its connectivity, function and involvement in behavior. The motor and limbic loops of the basal ganglia are important for processing of voluntary movement and emotions. During such physiological events, dopamine plays a central role in modulating the activity of these systems. The brain reward system is mainly formed by dopamine projections from the ventral tegmental area (VTA) to the ventral striatum. Certain dopamine neurons within the VTA exhibit the ability to co-release dopamine and glutamate. In paper I, glutamate and dopamine co-release was targeted and our results demonstrate that the absence of VGLUT2 in dopamine neurons leads to perturbations of reward consumption and reward-associated memory, probably due to reduced DA release observed in the striatum as detected by in vivo chronoamperometry. In papers II and IV, VGLUT2 in a specific subpopulation within the subthalamic nucleus (STN) was identified and targeted. Based on the described role of the STN in movement control, we hypothesized that the mice would be hyperlocomotive. As shown in paper II, this was indeed the case. In paper IV, a putative reward-related phenotype was approached and we could show reduced operant-self administration of sugar and altered dopamine release levels suggesting a role for the STN in reward processes. In paper III, we investigated and identified age- and sex-dimorphisms in dopamine kinetics in the dorsal striatum of one of the most commonly used mouse lines worldwide, the C57/Bl6J. Our results point to the importance of taking these dimorphisms into account when utilizing the C57/Bl6J strain as model for neurological and neuropsychiatric disorders.
60

Contribution of the subthalamic nucleus to visually guided locomotion

Yahiaoui, Nabiha 12 1900 (has links)
No description available.

Page generated in 0.0989 seconds